Podcasts about Biologic

Irina Turchin, MD, FRCPC, DABD / Hélène Veillette, MD, FRCPC - On the Case: Practical Insights to Individualize Biologic Treatment in Moderate-to-Severe Hidradenitis Suppurativa

Irina Turchin, MD, FRCPC, DABD / Hélène Veillette, MD, FRCPC - On the Case: Practical Insights to Individualize Biologic Treatment in Moderate-to-Severe Hidradenitis Suppurativa

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered how certolizumab pegol reduces anterior uveitis flares in high-risk axSpA and the effect of secukinumab dose escalation on MRI inflammation and damage in axSpA.

Keep up with the move toward targeted disease modifying therapies in Sjögren's disease. Credit available for this activity expires: 05/12/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/addressing-unmet-needs-management-sj%C3%B6grens-disease-2026a1000dvs?ecd=bdc_podcast_libsyn_mscpedu

Can someone with seropositive rheumatoid arthritis (high CCP, inflammatory synovitis, severe flare) go into full remission without long-term medication?In this powerful interview, Dr. Isabelle Amigues speaks with Brandon, a patient diagnosed with textbook rheumatoid arthritis who experienced:• Severe joint inflammation• High anti-CCP antibodies• Debilitating flares• Prednisone and methotrexate treatment• Biologic therapy (Kevzara)After a profound turning point, Brandon explored:• Vagus nerve stimulation• Stress reduction & nervous system regulation• Meditation & humming techniques• Anti-inflammatory nutrition• Exercise & muscle rebuilding• Body awareness & alignmentToday, he has been in full remission for over 6 months without medication.This episode explores:• The role of stress in autoimmune disease• Vagus nerve stimulation and inflammation• Can RA remission happen naturally?• The bridge between Western medicine and nervous system healing• Why remission is the goal — no matter the pathThis is not medical advice. This is a story of possibility, partnership, and personalized care.If you'd like access to our vagus nerve stimulation webinar, comment below.

Listen to our latest podcast as orthopedic clinician scientists, Dr Brian Feeley and Dr Drew Lansdown, break down what you need to know about stem cells in 2026. What exactly are they? Are their applications in orthopedic surgery? Who is a candidate?

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PRZ865. CME/MOC/CC/AAPA/IPCE credit will be available until April 20, 2027.Blocking Type 2 Inflammation in CRSwNP With Targeted Biologic Therapy: Personalizing Care to Achieve Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PRZ865. CME/MOC/CC/AAPA/IPCE credit will be available until April 20, 2027.Blocking Type 2 Inflammation in CRSwNP With Targeted Biologic Therapy: Personalizing Care to Achieve Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PRZ865. CME/MOC/CC/AAPA/IPCE credit will be available until April 20, 2027.Blocking Type 2 Inflammation in CRSwNP With Targeted Biologic Therapy: Personalizing Care to Achieve Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PRZ865. CME/MOC/CC/AAPA/IPCE credit will be available until April 20, 2027.Blocking Type 2 Inflammation in CRSwNP With Targeted Biologic Therapy: Personalizing Care to Achieve Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

Send us Fan MailWhat if paralysis wasn't permanent—but just a biological system we haven't figured out how to reboot?Dr. Lior Shaltiel, Ph.D. is Chief Executive Officer of NurExone Biologic ( https://nurexone.com/ ), a biotech company pioneering a novel exosome-based platform aimed at repairing the central nervous system.Dr. Shaltiel brings a rare combination of deep scientific training and cross-border biotech leadership. He earned his Ph.D. in molecular pharmacology from Ludwig Maximilian University of Munich, where his research focused on ion channels and retinal biology - early work that connects directly to today's frontier in neuroregeneration.Before stepping into the CEO role, Dr. Shaltiel led R&D programs in advanced drug delivery systems, including liposome-based therapeutics, and worked in global biotech investment and partnerships. He's also the founder of the BioMed MBA program at Hebrew University of Jerusalem, helping train the next generation of biotech leaders.At NurExone, Dr. Shaltiel is advancing the company's ExoTherapy platform - leveraging extracellular vesicles to deliver targeted genetic payloads. Their lead program, ExoPTEN, is an intranasal exosome therapy designed to silence the PTEN gene and promote neuronal regeneration after spinal cord injury - an area where, to date, there are no approved treatments that restore lost function.#biotech #neuroscience #spinalcordinjury #regenerativemedicine #exosomes #stemcells #futureofmedicine #geneediting #biotechinnovation #medicalbreakthrough #neuroregeneration #sciencepodcast #healthtech #longevity #drugdiscovery #PTEN #RNAi #nextgenmedicine #biophysics #medtechSupport the show

Dr Vicki Nahra from University Hospitals in Cleveland joins Suzanne to discuss biologic therapies available for lupus patients! Want to share your lupus story? Email our shows producer, Alex Acevedo, to book your appearance! Alex@lupusgreaterohio.org⁠Upcoming Events: https://linktr.ee/lupusgreateroh

Please visit answersincme.com/860/240201375-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James Michael Ramsahai, BSc, MD, PhD, FRCPC and Nan Zhao, BSc, MD, FRCPC. In this activity, experts in managing severe eosinophilic asthma discuss evidence-based strategies for personalizing biologic therapy, reducing steroid burden, and optimizing treatment in the setting of overlapping eosinophilic diseases. Upon completion of this activity, participants should be better able to: Identify strategies to individualize the selection of biologic therapies for patients with severe eosinophilic asthma based on the latest clinical and real-world evidence; Evaluate the implications of real-world data on biologic therapies for addressing airway remodeling and airway plugging; Develop steroid-sparing treatment plans and monitoring strategies for patients with severe eosinophilic asthma; and Formulate treatment plans to adjust the use of biologic therapies in patients with severe eosinophilic asthma and overlapping eosinophilic comorbidities.

Please visit answersincme.com/860/240201375-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James Michael Ramsahai, BSc, MD, PhD, FRCPC and Nan Zhao, BSc, MD, FRCPC. In this activity, experts in managing severe eosinophilic asthma discuss evidence-based strategies for personalizing biologic therapy, reducing steroid burden, and optimizing treatment in the setting of overlapping eosinophilic diseases. Upon completion of this activity, participants should be better able to: Identify strategies to individualize the selection of biologic therapies for patients with severe eosinophilic asthma based on the latest clinical and real-world evidence; Evaluate the implications of real-world data on biologic therapies for addressing airway remodeling and airway plugging; Develop steroid-sparing treatment plans and monitoring strategies for patients with severe eosinophilic asthma; and Formulate treatment plans to adjust the use of biologic therapies in patients with severe eosinophilic asthma and overlapping eosinophilic comorbidities.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/RJW865. CME/MOC credit will be available until March 3, 2027.Building on the Path in CRSwNP: Targeting Upstream Drivers With the Latest Biologic Approaches In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/RJW865. CME/MOC credit will be available until March 3, 2027.Building on the Path in CRSwNP: Targeting Upstream Drivers With the Latest Biologic Approaches In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/RJW865. CME/MOC credit will be available until March 3, 2027.Building on the Path in CRSwNP: Targeting Upstream Drivers With the Latest Biologic Approaches In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/RJW865. CME/MOC credit will be available until March 3, 2027.Building on the Path in CRSwNP: Targeting Upstream Drivers With the Latest Biologic Approaches In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

Biologics have changed how patients with asthma are able to handle their symptoms and prevent them from getting worse. Host Amy Attaway, MD, Cleveland Clinic, talks with Monica Kraft, MD, Icahn School of Medicine at Mount Sinai, and De De Gardner, DrPh, Allergy and Asthma Network and member of PAR about depemokimab, the newest biologic for those with severe asthma. Learn how this novel treatment is used once every six months to improve patient outcomes, as well as the research behind this biologic and the future of asthma treatment. Read Dr. Kraft's paper on depemokimab: https://journal.chestnet.org/article/S0012-3692(25)00855-4/pdf  Editor's note: During this episode, Dr. Kraft mistakenly said that depemokimab was approved for treating nasal polyps. Please note that depemokimab is not approved for treating this condition. 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UDD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 15, 2027.Treating With Precision in CRSwNP: Defining the Role of Targeted Biologic Therapy for Optimal Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UDD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 15, 2027.Treating With Precision in CRSwNP: Defining the Role of Targeted Biologic Therapy for Optimal Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UDD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 15, 2027.Treating With Precision in CRSwNP: Defining the Role of Targeted Biologic Therapy for Optimal Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UDD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 15, 2027.Treating With Precision in CRSwNP: Defining the Role of Targeted Biologic Therapy for Optimal Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UDD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 15, 2027.Treating With Precision in CRSwNP: Defining the Role of Targeted Biologic Therapy for Optimal Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

In this final episode of the Progesterone Promise series, Dr. Brendan McCarthy, Chief Medical Officer of Protea Medical Center, breaks down one of the most misunderstood hormones in women's health: progesterone. Progesterone is not “good” or “bad.” It's contextual. In today's world of quick sound bites and social media medicine, hormones are often reduced to oversimplified claims like “progesterone fixes anxiety” or “progesterone causes breast cancer.” The truth? It depends on your body, your stress levels, your liver health, your inflammation, your delivery method, and whether you're using bioidentical progesterone or synthetic progestins.   Citations: 1. Oral Progesterone → First-Pass Metabolism & Allopregnanolone Claim: Oral micronized progesterone undergoes significant hepatic first-pass metabolism, increasing neuroactive metabolites (especially allopregnanolone), which positively modulate GABA-A receptors and produce sedative/anxiolytic effects. Core Evidence: Simon et al., 1993; de Lignières et al., 1995; Freeman et al., 1990 — Oral progesterone produces measurable neuroactive metabolites. Paul & Purdy, 1992; Rupprecht et al., 2001 — Allopregnanolone enhances GABA-A receptor activity. Supports: Sedation variability by route • Neurosteroid generation • GABA-A modulation 2. Sulfation vs 5α-Reduction → Opposing Neurologic Effects Claim: Progesterone metabolites can produce calming (5α-reduced) or excitatory (sulfated) neurologic effects depending on enzyme routing. Core Evidence: Majewska et al., 1990 — Pregnenolone sulfate negatively modulates GABA-A. Wu et al., 1991 — Sulfated neurosteroids enhance NMDA signaling. Schumacher et al., 2007; Reddy, 2010 — Pathway reviews of sulfation vs 5α-reduction. Supports: Reverse responding hypothesis • Divergent neurologic experiences • Enzyme-dependent effects 3. Stress & Enzyme Modulation Claim: Chronic stress alters HPA axis tone and hepatic enzyme expression, influencing steroid metabolism balance. Core Evidence: McEwen, 1998 — Allostatic load model. Charmandari et al., 2005 — Cortisol's systemic regulatory effects. Zanger & Schwab, 2013; Gibson & Skett, 2001 — Stress alters cytochrome P450 expression. Supports: Stress-biased metabolism • Context-dependent hormone response 4. Breast Tissue Signaling & Context Claim: Progesterone influences mammary differentiation and interacts with estrogen signaling in context-dependent ways. Core Evidence: Brisken & O'Malley, 2010 — Progesterone receptor biology in breast tissue. Beleut et al., 2010 — RANKL mediates progesterone-driven proliferation. Hofseth et al., 1999 — PR-ER signaling interaction. Stanczyk & Bhavnani, 2014 — Natural vs synthetic differences in breast effects. Supports: Lobuloalveolar differentiation • RANKL pathway • Context-dependent proliferation 5. Synthetic Progestins vs Bioidentical Progesterone Claim: Synthetic progestins differ structurally and bind off-target receptors, producing distinct tissue effects. Core Evidence: Stanczyk et al., 2013 — Receptor binding differences. Sitruk-Ware, 2004 — Biologic comparisons. Chlebowski et al., 2003 (WHI) — Breast cancer signal with CEE + MPA. Supports: Structural divergence • Receptor-level differences • WHI clarification 6. Route of Delivery Differences Claim: Oral, vaginal, transdermal, and sublingual progesterone produce distinct pharmacokinetic profiles and tissue targeting. Core Evidence: Simon, 1995 — Oral vs vaginal PK comparison. Cicinelli et al., 2000 — “First uterine pass effect.” Wren et al., 2003 — Route-dependent systemic levels. Supports: Uterine targeting • Neurosteroid variability • Sedation differences 7. Progesterone, PMS & Migraine Claim: Neurosteroid fluctuations influence GABAergic tone and may contribute to PMS and migraine susceptibility. Core Evidence: Backstrom et al., 2011 — Allopregnanolone fluctuations in PMS. Reddy & Rogawski, 2002 — Neurosteroids and seizure threshold. Martin & Behbehani, 2001 — Hormonal fluctuations and migraine. Supports: Luteal neurosteroid shifts • GABA instability • Migraine association   Dr. Brendan McCarthy is the founder and Chief Medical Officer of Protea Medical Center in Arizona. With over two decades of experience, he's helped thousands of patients navigate hormonal imbalances using bioidentical HRT, nutrition, and root-cause medicine. He's also taught and mentored other physicians on integrative approaches to hormone therapy, weight loss, fertility, and more. If you're ready to take your health seriously, this podcast is a great place to start.  

During last year's PEGS Europe, industry experts gathered on a panel to discuss the future of biologic therapeutics. The panel kicked off with a presentation on 50 years of monoclonals, from hybridomas to next-gen antibody therapeutics, followed by a conversation featuring Paul Carter, Ph.D., Genentech Fellow of Antibody Engineering, G. Jonah Rainey, Ph.D., associate vice president of Eli Lilly and Company, and Janine Schuurman, Ph.D., biotech consultant at Lust for Life Science B.V. Moderated by Daniel Chen, M.D., Ph.D., founder and CEO of Synthetic Design Lab, the discussion centered around whether half-life extended peptides will eventually replace multispecific antibodies. Links from this episode:  PEGS Europe  PEGS Synthetic Design Lab Genentech Eli Lilly and CompanyLust for Life Science B.V. 

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Paresh Vyas and Andrew Hantel on their research published in this week's issue of Blood. Dr. Vyas discusses his paper, "Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy", which provided new insights as to when and how to intervene to circumvent resistance to AML remission. Dr. Hantel will speak about his paper, "Impact of Modernizing Eligibility Criteria on Enrollment and Representation in AML Clinical Trials". For a real-world cohort of more than 2200 patients with AML, they reported that modernized, safety-based criteria could nearly double trial eligibility, with especially pronounced gains among historically underserved groups.  Both studies highlight how biologic insight and thoughtful trial design can drive more effective, inclusive advances in AML treatment and research. 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FTW865. CME/MOC/AAPA/IPCE credit will be available until January 25, 2027.ECHOing Innovation in COPD: Transforming Patient Care With the Use of Targeted Biologic Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FTW865. CME/MOC/AAPA/IPCE credit will be available until January 25, 2027.ECHOing Innovation in COPD: Transforming Patient Care With the Use of Targeted Biologic Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FTW865. CME/MOC/AAPA/IPCE credit will be available until January 25, 2027.ECHOing Innovation in COPD: Transforming Patient Care With the Use of Targeted Biologic Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FTW865. CME/MOC/AAPA/IPCE credit will be available until January 25, 2027.ECHOing Innovation in COPD: Transforming Patient Care With the Use of Targeted Biologic Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

Please visit answersincme.com/860/240201321-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Neda Amiri, MD, MHSc, FRCPC, ABIM; Dharini Mahendira, MD, FRCPC, MScCH and Eleftherios Soleas, PhD. In this activity, experts in rheumatology discuss evidence-based strategies to facilitate the selection and optimization of biologic therapies in women with inflammatory arthritis who are of childbearing potential. Upon completion of this activity, participants should be better able to: Describe how patient-specific factors, including fertility status, pregnancy, and lactation, inform personalized biological therapy selection in inflammatory arthritis; Evaluate the efficacy and safety profiles of approved biologics in women of childbearing potential across inflammatory arthritis indications; and Apply strategies to optimize management decisions in reproductive-age women with inflammatory arthritis.

Fierce First Step in 2026 PodcastFIVE PRIMARY POINTS of the PODCASTLiving in the “Vitality Zone” Requires Conscious Choice and CourageDr. Mishra contrasts the vitality zone—where life feels purposeful, energetic, and engaged—with the surviving, sliding, and burnout zones. Using his experience standing on Iceland's continental divide as a metaphor, he emphasizes that meaningful growth often requires a deliberate leap of faith rather than passive autopilot living.Sleep is the New Frontier for Disease PredictionGroundbreaking AI research (the Sleep Foundation Model) shows that data from a single night of sleep can predict over 130 health conditions, including dementia, heart disease, stroke, and all-cause mortality. Sleep is reframed not as passive rest, but as a powerful diagnostic signal for future health.Sleep Functions as a Biological and Metabolic SuperpowerHigh-quality sleep resets metabolism, reduces inflammation, preserves muscle mass, improves cognition, and enhances physical performance. Athletes, professionals, and everyday individuals perform better when sleep is prioritized, making it foundational for both vitality and productivity.Five Evidence-based Principles can Dramatically Improve Sleep QualityThe most impactful strategies are:* Prioritizing sleep regularity over total sleep duration* Using exercise (especially strength training) as a drug-free sleep aid* Executing consistent sleep hygiene (cool, dark room; limited screens/caffeine; calming routines)* Recognizing sleep as a performance enhancer and metabolic reset* Treating sleep data as a validated biomarker for long-term health riskKnowledge only Matters when Turned into ActionEchoing Benjamin Franklin, Dr. Mishra stresses that while knowledge pays dividends, action pays more. The concrete vitality action for the week is simple but powerful: aim for 20 additional minutes of quality sleep per night, combined with moments of stillness, reflection, and self-advocacy to move intentionally toward a more vital life.Copyright VyVerse, LLC. All Rights Reserved. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit vitalityexplorers.substack.com/subscribe

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZYK865. CME/MOC/CC/AAPA credit will be available until December 15, 2026.Tackling CRSwNP Management With Emerging Biologic Therapies Targeting Epithelial Cytokines: Game On! In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZYK865. CME/MOC/CC/AAPA credit will be available until December 15, 2026.Tackling CRSwNP Management With Emerging Biologic Therapies Targeting Epithelial Cytokines: Game On! In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

Join me for a fascinating deep dive into the science of immune aging with Dr. Natalia Mitin, founder and CEO of Sapere Bio. We explore why the aging of the immune system is the primary driver of aging for the entire body and unpack the concept of cellular senescence—often called "zombie cells"—where stressed cells persist and create chronic inflammation. Dr. Mitin explains why consumer tests that assign a specific "biological age" in years are often scientifically lacking compared to measuring where you stand within a population's trajectory. We also discuss cutting-edge longevity targets, including T-cell exhaustion (and how drugs like Rapamycin and SGLT2 inhibitors address it), the critical role of gut health (where 70% of the immune system resides), and how mitochondrial function in stem cells can correlate with an extra 15 years of healthspan.

December 13, 2025 | What is next for immunogenicity? In this episode of The Chain, Vibha Jawa, chief scientific officer at EpiVax, provides her thoughts and insights on BiTE molecules, pegylated molecules, and other biologic molecules and their impact on cancer treatment and research with host Rakesh Dixit. Jawa shares the most rewarding project she's worked on and what therapeutic modality she sees being picked up in the next decade, as well as advice for the next generation of scientists, such as why it's important to be hands-on with research and be collaborative with others.  Links from this episode:  EpiVax 

On each of these mini episodes, Catherine and I chat about a new article or new surgical technique in the field of sports medicine. We'll give you our quick take on the most recent data and how this data will impact our practice. Today, we're discussing a brand-new paper hot off the press titled: “Predictors of Tunnel Widening After Anterior Cruciate Ligament Reconstruction” published in the November 2025 issue of AJSM. This study digs into why femoral and tibial tunnels enlarge after ACL reconstruction with hamstring grafts – and what anatomic and surgical factors might be driving it.Tunnel widening matters: it impacts revision surgery, graft stability, and in some cases early failures. So, this is a clinically meaningful topic. We will start with some background. Tunnel widening after ACL reconstruction is not new…but why it happens is debated. There are a few proposed mechanisms:·       Biologic factors: synovial fluid ingress, cytokines, graft necrosis, remodeling.·       Mechanical factors: graft motion (“windshield wiper” / “bungee effect”), repetitive shear.·       Anatomic factors: posterior tibial slope increasing anterior tibial translation forces.·       Surgical factors: fixation method, tunnel position, graft choice (hamstring vs BTB or Quad). This study asked three key questions:1.     Does posterior tibial slope (PTS) predict tunnel widening?2.     Do meniscus root tears contribute?3.     Does adding a lateral extra-articular tenodesis (LET) influence tunnel change? ·       This is the first large cohort looking at all these together over 2 years, with both tibial and femoral tunnel measurements. ·       The study included 307 patients who underwent primary ACL reconstruction using hamstring autograft. The femoral and tibial tunnels were measured immediately postop and again at 2 years.  Medial and lateral posterior tibial slope was measured on long-leg lateral radiographs.  The authors also looked at the incidence of additional LET, meniscus root injury and BMI.·       They used univariate and multivariate regression to determine independent predictors.So, what did they find? Tune in and enjoy the episode!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PTU865. CME/MOC/AAPA credit will be available until December 12, 2026.Addressing an Exacerbating Issue in COPD: Strategies for Individualized Targeted Biologic Therapy to Improve Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PTU865. CME/MOC/AAPA credit will be available until December 12, 2026.Addressing an Exacerbating Issue in COPD: Strategies for Individualized Targeted Biologic Therapy to Improve Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PTU865. CME/MOC/AAPA credit will be available until December 12, 2026.Addressing an Exacerbating Issue in COPD: Strategies for Individualized Targeted Biologic Therapy to Improve Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

Be Kind & Grateful to Be Great PodcastFIVE PRIMARY POINTS of the PODCASTHuman Connection Matters More Than DataDr. Mishra opens with Dean Ornish's idea that connection and community are as essential as food, water, and air. He argues we are drowning in data but starving for direction, and asks listeners to stop tracking themselves for a week and intentionally engage with real humans.Biomarkers Alone Cannot Measure VitalityDespite years of research—including PRP innovation and extensive self-testing—Dr. Mishra emphasizes that no single biomarker or panel can accurately quantify vitality. He critiques the booming longevity-tech market for offering more marketing than science.The Hottest Longevity Tests Have Limited EvidenceHe reviews four major categories:* Blood-based biomarker panels: Huge market but very little peer-reviewed evidence supporting meaningful insights.* Microbiome testing: Promising but still early; diverse gut bacteria correlate with healthier aging.* Biologic clocks (epigenetic, facial, retinal): Interesting but inconsistent, easily cherry-picked, and not yet clinically integrated.* Liquid biopsies & whole-body MRI: Useful mainly for high-risk populations; false positives can cause harm.Overall: science lags far behind the hype.The Best Ways to Slow Biological Aging Are Proven and SimpleBased on published data, the most reliable methods to slow biological aging remain:* Consistent physical activity* High-quality sleep* Calorie restriction* Plant-forward diet* Optimal vitamin D* Higher income* Higher educationA Hybrid Future: Start With Human Vitality, Then Add TechDr. Mishra recommends:* Prioritizing human actions AI cannot do—forgiveness, fun, imagination, courage, resilience, service, connection.* Considering comprehensive testing at two strategic “warranty expiration” stages: early 40s and late 50s.* Building a future where human vitality comes first, and elite technology augments—not replaces—our humanity.Copyright, VyVerse, LLC. All Rights Reserved. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit vitalityexplorers.substack.com/subscribe

Dr. Michelle is an author, speaker, educator, biologic/holistic dentist, and wellness advocate dedicated to helping people live healthier, more vibrant lives.   For over a decade, she practiced traditional dentistry until her own health crisis revealed the hidden dangers of mercury exposure. After being diagnosed with mercury poisoning—caused by years of removing mercury fillings—Michelle began a personal journey to restore her health. That journey transformed not only her career but also her life's purpose.   Through extensive study and experience, she discovered natural, practical ways to heal and thrive—finding solutions in the kitchen, the garden, and everyday living.    Today, as the founder of Living Well with Dr. Michelle, she shares her knowledge to empower individuals and families to create a healthier lifestyle through simple, sustainable changes.   Timestamps (may vary by 2-4 minutes depending on your podcast platform)    02:55 Introduction to Holistic Dentistry 03:55 Michelle's Health Journey and Discovery of Mercury Poisoning 09:52 Transitioning to Holistic Practices in Dentistry 17:44 Understanding Mercury Fillings and Safe Removal 25:49 The Fluoride Debate and Its Implications 27:04 Innovative Solutions: Hydroxyapatite Products for Dental Health 27:46 The Importance of Minerals and Vitamins for Dental Health 33:04 Best Practices for Maintaining Healthy Teeth 38:00 Understanding Dental Implants and Cosmetic Dentistry 48:27 Hidden Dangers of Wisdom Teeth Removal   (Website) https://livingwellwithdrmichelle.com/   (Facebook) www.facebook.com/livingwellwithdrmichelle   (Instagram) www.instagram.com/livingwellwithdrmichelle/   (Youtube) www.youtube.com/c/LivingwellwithDrMichelle   (Tiktok) www.tiktok.com/@livingwellwithdrmichelle  

Please visit answersincme.com/PME860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) discuss strategies for optimizing the detection and management of CRSwNP, with a focus on the role of biologics in patient-centered care. Upon completion of this activity, participants should be better able to: Identify best practices to facilitate the early detection of CRSwNP; Discuss the risk-benefit profiles of approved and emerging biologics for the treatment of CRSwNP; and Identify patient-centered, multidisciplinary strategies to integrate biologics into the treatment algorithm for patients with CRSwNP.

Injection Molding PDF Email me: dr.melissaseibert@gmail.com Join Elevated GP: www.theelevatedgp.com Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram In this second installment of Dental Digest's conversation with Dr. Jonathan Esquivel, host Dr. Melissa Seibert and her guest push deeper into the artistry, biology, and discipline required to restore anterior implants that are as functional as they are beautiful. While Part 1 introduced Esquivel's framework of space, volume, and time, this episode focuses on the next frontier—provisionalization, emergence-profile design, and the E-B-C concept that defines the biologic foundations of aesthetic implant therapy. Dr. Esquivel begins by demystifying the provisionalization workflow for anterior implants—whether immediate or delayed. He walks listeners step by step through decision-making factors such as ridge healing, tissue phenotype, and the importance of minimizing the number of disconnections to protect the fragile mucosal seal. He stresses that efficiency in implant dentistry isn't about finishing fast—it's about achieving predictability in the fewest biologically respectful appointments. The discussion then turns to the team-based dynamics between the restorative dentist and the surgeon. Dr. Esquivel details how he coordinates cases digitally, sending STL files and mock-ups for joint planning before the first incision. His six-phase system—Acquisition, Blueprint, Confirmation, Design, Execution, and Follow-up—illustrates how restorative-driven implant dentistry must begin with facial and prosthetic design, not with a drill guide. From there, the episode dives into the chairside artistry of immediate provisionalization. Using a pre-milled shell and temporary cylinder, Dr. Esquivel describes how to "pick up" a provisional and sculpt the subgingival contours in real time. But as he emphasizes, the true challenge lies not in fabrication—but in understanding how material additions and reductions influence soft-tissue behavior. This insight leads to one of the most clinically valuable segments of the episode: Dr. Esquivel's E-B-C concept, an evolution of the classic critical- and subcritical-contour framework. The E-Zone (Esthetic Zone), roughly the first millimeter below the gingival zenith, governs margin stability and the visible pink–white transition. The B-Zone (Biologic or Boundary Zone) supports the mucosal seal and should remain concave to create space for healthy soft tissue. The C-Zone (Crestal Zone), the most apical 1–2 mm, must be slim and biologically quiet to preserve the crestal bone. Dr. Esquivel explains how even subtle over-contouring in these zones can trigger recession or bone loss, while proper shaping promotes long-term harmony between implant and tissue. Using tactile language, he describes his preference for pear-shaped acrylic burs to sculpt the concavity of the B-zone, and how digital workflows now allow clinicians to model these micro-contours virtually before any material is placed. The conversation culminates in a reflection on philosophy as much as technique. Dr. Esquivel urges clinicians to focus on mastering the basics—aesthetic symmetry, biologic respect, and patience—rather than chasing novelty. "An implant is not a tooth," he reminds us. "Our goal is to protect the bone, guide the tissue, and understand what we can't see." Listeners will leave this episode with a detailed understanding of: How to design, print, or fabricate custom provisionals that shape the soft tissue biologically The dimensional logic behind the E-B-C zones and how each governs tissue stability Why limiting abutment disconnections preserves the mucosal seal How digital and analog workflows can be integrated seamlessly And the mindset shift required to see implants not as prosthetic devices, but as biologic restorations Part 2 is both a masterclass in subgingival design and a meditation on restraint. Dr. Esquivel reminds us that excellence in implant aesthetics doesn't come from doing more—it comes from doing less, but with absolute intention.

Injection Molding PDF Email me dr.melissaseibert@gmail.com  Join Elevated GP: www.theelevatedgp.com Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram In this episode of Dental Digest, Dr. Melissa Seibert sits down with prosthodontist and educator Dr. Jonathan Esquivel for part one of an enlightening two-part series that explores the biologic and aesthetic complexities of implant restoration. Known for his meticulous approach and his evidence-based framework of space, volume, and time, Dr. Esquivel brings clarity to one of dentistry's most challenging frontiers: the anterior aesthetic zone. They begin by examining why restoring a single anterior implant is often considered the ultimate test of restorative mastery. Dr. Esquivel explains that implants behave fundamentally differently from natural roots—they lack the periodontal ligament and its vascular support—making soft tissue far less forgiving. Even slight changes in tissue contour or bone volume can compromise long-term success. He introduces his four cornerstones for implant predictability: luck (biologic variability), three-dimensional positioning, emergence-profile design, and patient maintenance, emphasizing that precision and patient education are inseparable. The conversation then turns to three-dimensional implant positioning and the role of reverse-engineered planning. Dr. Esquivel insists that every implant must begin with the end in mind—by first visualizing where the tooth should be. He details how ideal placement, roughly 4 mm apical to the planned incisal edge and aligned toward the cingulum, forms the foundation for natural emergence and long-term stability. But true success, he notes, depends equally on interdisciplinary collaboration—sometimes requiring orthodontic repositioning or periodontal modification before an implant is ever placed. Dr. Esquivel and Dr. Seibert next tackle the aesthetic challenge of adjacent implants and the pursuit of symmetry. Perfect papillae between centrals are notoriously difficult to maintain, and Dr. Esquivel discusses techniques—from soft-tissue grafting to orthodontic extrusion—to preserve harmony between the pink and the white. He stresses that treatment planning is as much about patient selection and expectation management as it is about surgical technique: "The hardest part isn't the implant—it's finding a patient willing to go through the process." The discussion deepens into the critical role of soft tissue in achieving lasting aesthetics. Dr. Esquivel explains his distinction between margin-preservation therapies (maintaining existing tissue contours) and margin-re-establishment therapies (rebuilding lost dimensions). He makes a compelling case that most anterior implants benefit from connective-tissue grafting, since thicker tissue phenotypes promote margin stability, mask restorative materials, and protect against recession. From there, the episode explores ridge dimensional changes after extraction—why bone and soft-tissue collapse are inevitable without intervention, and how provisional restorations can slow this process. Dr. Esquivel cautions against relying on removable flippers, which may accelerate resorption, and instead advocates for properly designed Essix retainers or fixed provisionals that maintain space without transmitting occlusal pressure. His guiding principle: space, volume, and time—allowing tissue to heal in an environment that supports both biological integrity and aesthetic form. The conversation culminates with an in-depth reflection on the biological and prosthetic purpose of provisionalization. Drawing on insights from Dr. Todd Schoenbaum, Dr. Esquivel reframes the provisional phase not as optional, but as biologically mandatory. The provisional guides tissue healing, allows for gradual adaptation, and provides essential information for the ceramist—ensuring that the final crown replicates the ideal emergence contours established chairside. As Dr. Esquivel puts it, "Dentists should take credit not for the white, but for the pink—the transition zone we've designed and stabilized." By the end of this episode, listeners will gain a detailed understanding of: How to apply Dr. Esquivel's space–volume–time model to aesthetic implant planning The biologic reasoning behind connective-tissue grafting and margin-preservation therapies Why provisionalization is central to both soft-tissue stability and prosthetic accuracy How to communicate healing timelines and realistic expectations to patients Part one of this series is both technically rigorous and refreshingly human—an exploration of how aesthetic implant success lies not in speed or convenience, but in respecting biology, sequencing, and time.

Injection Molding PDF Email me: Dr.melissaseibert@gmail.com Join Elevated GP: www.theelevatedgp.com Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram Episode Summary In this powerful continuation of their two-part conversation, Dr. Melissa Seibert and Dr. David Attia dive beyond digital workflows to confront the deeper philosophical questions shaping modern implant dentistry. Building on last week's discussion of data stacking, SmileCloud integration, and biologically driven design, this episode explores the nuanced realities of aesthetic-zone decision-making, ethical treatment planning, and the human side of high-level clinical care. Dr. Attia opens with an unflinching look at when—and why—implants may not be the ideal solution. Using examples from his collaboration with renowned prosthodontist Dr. Tony Rotondo, he explains why lateral incisors often perform better with resin-bonded fixed partial dentures (FDPs) rather than implants, especially in cases with limited mesiodistal space or compromised interproximal bone. He and Dr. Seibert examine the synergy between partial extraction therapy and resin-bonded FDPs, illustrating how biologic preservation can achieve long-term aesthetic stability with less surgical intervention. From there, the conversation transitions to Attia's mastery of provisionalization strategies in the aesthetic zone. He details how he designs custom healing abutments and Maryland-style bridges that provide patients with fixed provisionals—even when primary stability is limited. Listeners gain an inside look at his precision-driven process for contouring the subcritical zone, controlling soft-tissue architecture, and creating minimal yet functional clearance between the pontic and abutment. His philosophy is simple but profound: every anterior patient should leave the chair with something fixed—even if it isn't load-bearing. The discussion then widens to tackle the moral tension between commercial dentistry and biologic integrity. Dr. Seibert asks the hard question: How do clinicians reconcile high-quality, time-intensive dentistry with the economic pressures of high-volume practice? Dr. Attia's answer is unequivocal—ethical dentistry may take longer and require greater effort, but the money follows the mastery. He critiques the growing trend of overtreatment in both restorative and surgical spheres, warning of a coming wave of revision cases born from expedience and over-commercialization. Attia advocates for a "longevity-first" mindset—prioritizing preservation over replacement, patient education over production, and sustainable outcomes over speed. Drawing from his own follow-ups across fourteen practices, he reflects on the humility and evolution that come with long-term case review: what he did six months ago wasn't wrong—but it can always be better. The episode concludes with a candid meditation on values alignment in practice. Both clinicians emphasize the importance of knowing one's philosophy, communicating it transparently, and being comfortable acknowledging that "you're not everyone's dentist." Attia urges younger practitioners to resist the social-media allure of aggressive full-arch cases, reminding them that truly exceptional dentistry begins with sound biologic principles, refined communication, and disciplined restraint. Listeners will leave this episode with: A framework for choosing between implants and resin-bonded FDPs in the aesthetic zone Strategies for designing custom provisionals that maintain soft-tissue integrity Guidance on educating patients about biologic and financial "costs" of treatment Insight into navigating the ethical crossroads of modern dentistry This conversation is both technical and deeply human—a masterclass on how to balance innovation with integrity and how to practice dentistry that endures not just biologically, but ethically.

Okay, let's be honest—when was the last time you really thought about your dental work? Probably never.But what if I told you that old filling, root canal, or even just skipping floss isn't just about your teeth—it could actually be what's messing with your hormones, draining your energy, and keeping you stuck?Today's episode is going to blow your mind… and maybe have you calling your dentist.(Or looking for a new one!)In this episode we are chatting with Dr. Michelle Jorgensen, a trailblazer in the world of Biologic and Holistic Dentistry. She's an author, speaker, and teacher who had to completely reinvent her career after discovering that her own dental work was making her dangerously sick.And through her healing journey, she uncovered some of the shocking risks most of us never even consider when it comes to modern dentistry—things like mercury poisoning, hidden infections, root canals, and how they're all connected to your hormones, your immune system, and even your gut.Now, through her practice at Total Care Dental, she's helping people from around the world get their health back—starting with their mouth.----------You can find Dr. Michelle Jorgensen at livingwellwithdrmichelle.comOr she's @livingwellwithdrmichelle on YouTube, Instagram, Facebook, and TikTok. And you can get 10% off her Living Well products with code: Ruth10----------Get our FREE guide to finally fix your metabolism!Losing weight & getting healthy is never easy, but lately you might feel like it's suddenly become impossible.Our Flip the Switch guide will help you clearly understand what's been going on, as well as exactly what you can do to get your metabolism working again so that you can look and feel your best—it's easier and more simple than you think! Get it HERE.Check out Seven Sons and use coupon code: TL50 for $50 off your first box.